EQT Corporation has earned an A grade for value in the latest Zacks Style Scores report, reflecting its attractive valuation metrics relative to peers in the energy sector. The company’s trailing price-to-earnings ratio stands at approximately 11.8 times, well below the peer group average of 15.2, while its price-to-cash-flow ratio of 3.5 suggests ample free cash generation. EQT’s forward dividend yield of around 2.6% further bolsters its income appeal, supported by a payout ratio near 25%. Investors seeking a low-risk entry point may view these metrics as evidence that EQT is trading at a meaningful discount to its intrinsic value.

EQT has confirmed it approached Oxford BioMedica with a proposal for a cash acquisition, according to a joint statement issued by both companies following market close on Wednesday. The unsolicited approach comes after Oxford BioMedica’s shares gained over 30% since January, driven by speculation of strategic interest. EQT, the Stockholm-listed private equity group managing roughly €84 billion in assets, is reportedly evaluating a deal that would bolster its presence in the gene-therapy manufacturing sector. While no formal offer has been tabled, board directors from both sides will convene this month to explore transaction structuring, expected to include customary due diligence and regulatory review steps.